Actinium Pharmaceuticals, Inc. announced that it has appointed the members of its Nuclear Medicine Clinical Advisory Board. Members are David Colcher, Ph.D., Johannes Czernin, M.D., Ghassan El-Haddad, M.D., Dan Pryma, M.D., Franklin Wong, M.D., Ph.D., J.D., Michael Yu, M.D. Actinium is developing Antibody Radio-Conjugates (ARCs) that combine the targeting capabilities of monoclonal antibodies with the cell kill ability of radioisotopes. Actinium’s most advanced ARC, Iomab-B, targets CD45 and is currently being studied in a pivotal Phase 3 trial for targeted conditioning prior to a bone marrow transplant, which is a potentially curative treatment option for patients with a number of hematologic diseases. Actinium is also developing its CD33 program that is being studied in 5 Phase 1 and Phase 2 trial for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma, which all express CD33. Recognizing the importance of the nuclear medicine community to its ARC drug candidates, Actinium has formed Nuclear Medicine Clinical Advisory Board in anticipation of continued clinical development expansion and potential commercialization of Iomab.